Imidazolone and oxazolone derivatives as dopamine antagonists

• Main Authors: KEVIN WILLIAM MOORE, WILLIAM ROBERT CARLING
• Format: Patent
• Language: English
• Published: 23.10.1997
• Edition: 6
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PCT No. PCT/GB94/01934 Sec. 371 Date Mar. 12, 1996 Sec. 102(e) Date Mar. 12, 1996 PCT Filed Sep. 6, 1994 PCT Pub. No. WO95/07904 PCT Pub. Date Mar. 23, 1995A class of imidazolone and oxazolone derivatives of Structure I, (I) wherein X represents oxygen or N-R1; Q represents a substituted five-, six- or seven-membered monocyclic heteroaliphatic ring which contains one nitrogen atom as the sole heteroatom and is linked to the imidazolone or oxazolone ring via a carbon atom; R1 represents hydrogen or C1-6 alkyl; and one of R2 and R3 represents hydrogen or C1-6 alkyl and the other of R2 and R3 represents cycloalkyl or a group of formula (i), (ii) or (iii): (i) (ii) (iii) in which Z represents oxygen, sulphur or NH; R4, R5 and R6 independently represent hydrogen, a hydrocarbon group or a heterocyclic group wherein the hydrocarbon group and heterocyclic group are as defined in the specification; or a pharmaceutically acceptable salt or prodrug thereof, which are ligands for dopamine receptor subtypes within the brain and are therefore of use in the treatment and/or prevention of disorders of the dopamine system, such as schizophrenia.